Evidence map›Paper›PMID 23837753›Full record

ArticleFuture oncology (London, England)2013

The potential for targeting the STAT3 pathway as a novel therapy for melanoma.

Gregory B Lesinski

Abstract readEditorial
In one paragraph

Article in Future oncology (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. STAT3 activation in infection and infection-associated cancer.Molecular and cellular endocrinology · 2017
    Review
  14. Article
  15. Article
  16. Other targeted drugs in melanoma.Annals of translational medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gregory B Lesinski

Funding

Optimizing selective in vivo inhibition of pancreatic tumor JAK2/STAT3 signalingR21CA173473 · NCI · OHIO STATE UNIVERSITY · PI PHELPS, MITCH A · 2013 to 2014
$373k
NCI NIH HHS 1R21 CA173473-01NCI NIH HHS R21 CA173473
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsDrug DesignDrug Resistance, NeoplasmHumansIndolesMelanomaMiceMolecular Targeted TherapyRNA, Small InterferingSTAT3 Transcription FactorSulfonamidesVemurafenibAntineoplastic AgentsIndolesRNA, Small InterferingSTAT3 protein, humanSTAT3 Transcription FactorSulfonamidesVemurafenib

Identifiers

PMID23837753
PMCPMC3801207

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.